Search

Displaying results 6071 - 6080 of 7540 in total
  1. Drug

    Cephalothin Group

    go.drugbank.com/drugs/DB03450
    Experimental

    This compound belongs to the 1,3-thiazines. … This substance is known to target beta-lactamase Toho-1 and D-alanyl-D-alanine carboxypeptidase.

  2. Drug

    Lepzacitinib

    go.drugbank.com/drugs/DB21646
    Investigational

    Lepzacitinib is under investigation in clinical trial NCT05432596 (Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis).

  3. Drug

    Alunacedase alfa

    go.drugbank.com/drugs/DB15736
    Investigational

    Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.

  4. Drug

    HM15912

    go.drugbank.com/drugs/DB18266
    Investigational

    HM15912 is a human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment.

  5. Drug

    AG-24322

    go.drugbank.com/drugs/DB13035
    Investigational

    AG-024322 has been used in trials studying the treatment of Neoplasms and Lymphoma, Non-Hodgkin.

  6. Drug

    GDC-0349

    go.drugbank.com/drugs/DB13072
    Investigational

    GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor.

  7. Drug

    Ramoplanin

    go.drugbank.com/drugs/DB04952
    Experimental

    Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.

  8. Drug

    Budigalimab

    go.drugbank.com/drugs/DB16668
    Investigational

    With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis). … Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination

  9. Drug

    AZD7442

    go.drugbank.com/drugs/DB15787
    Investigational

    [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]

  10. Drug

    Luvometinib

    go.drugbank.com/drugs/DB21696
    Investigational

    Luvometinib is under investigation in clinical trial NCT07004075 (FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration).